Tirzepatide Price Comparison — Compare 24 Vendors

View full research →
Metabolic / weight researchSafety Rating 8/10
Compared to FDA-approved pricing

Save ~98% vs Zepbound LillyDirect (single-dose vials)

Mounjaro (T2D) / Zepbound (weight loss)Zepbound LillyDirect (single-dose vials)
$349/mo
CVS / Walgreens cash retail
$1,059/mo
Research-grade TirzepatidePeptidePrices · cheapest verified
$6/mo

Research-grade Tirzepatide is for laboratory and research use only, not approved for human consumption. Always consult a licensed physician before working with any compound. FDA-approved 2022 (Mounjaro) and 2023 (Zepbound). Eli Lilly's direct-to-consumer vial program brought cash-pay floor to $349 for 2.5mg starter doses.

See all Tirzepatide vendors →

Price Comparison

Compare vendors · per 5mg

24 vendors competing

VendorPrice$ / mgUpdated
Alpha Peptides8/10$76.49$84.99−10% · code PEPTIDEPRICES10$1.27Jun 12, 2026Buy →
Puratek Peptides9.5/10$80.95$89.95−10% · code PEPTIDEPRICES$1.35May 19, 2026Buy →
Red River Peptides6/10$93.50$110.00−15% · code PEPTIDEPRICES$1.56May 19, 2026Buy →
Hydro Research9/10$625.00$1250.00−50% · code PEPTIDEP50$2.08Jun 5, 2026Buy →
Midwest Peptide8.5/10$80.99$89.99−10% · code PEPTIDEPRICES$2.70Jun 18, 2026Buy →
Glacier Aminos9.5/10$165.59$183.99−10% · code peptidep$2.76Jun 23, 2026Buy →

Research details

Tirzepatide — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range2.5–15 mg SC weeklysource ↗
AdministrationSubcutaneous injection
Half-life~5 days
Safety8/10 · FDA-approved (Mounjaro/Zepbound)
NCAA D1Not listed

Overview

About Tirzepatide

Mechanism of action

Dual GIP and GLP-1 receptor agonist. Enhances insulin secretion, reduces glucagon, suppresses appetite, slows gastric emptying, improves insulin sensitivity.

Safety profile

Nausea, vomiting, diarrhea, decreased appetite, constipation, pancreatitis risk, gallbladder issues, thyroid tumor risk (theoretical). · Extensive Phase III data; GI side effects manageable; thyroid warning animal-only; strong efficacy

Storage

Stability & handling

❄️Lyophilized (powder)−20°Clong-term stable
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Safety & Interactions

Contraindications & Drug Interactions

Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.

⚠ CriticalContraindication

Personal or family history of medullary thyroid carcinoma (MTC). FDA black-box warning.

⚠ CriticalContraindication

MEN 2 syndrome.

⚠ CriticalContraindication

Prior serious hypersensitivity reaction.

Sources: FDA

The vendors above are research-use-only. Want the legal, doctor-prescribed route instead? Get it prescribed online by licensed US providers and shipped from state-licensed US pharmacies.

See telehealth options →

Related pages

More on Tirzepatide

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • SURMOUNT-1 (NEJM 2022, n=2,539) established tirzepatide as the most efficacious approved obesity pharmacotherapy at the time — the 15 mg dose achieved a mean 22.5% body weight reduction vs 2.4% with placebo over 72 weeks, with 57% of participants achieving ≥20% weight loss.
  • SURMOUNT-2 (Lancet 2023) confirmed tirzepatide's efficacy in adults with both obesity and T2D, with the 15 mg dose achieving -14.7% weight change vs -3.2% with placebo — and improvements in HbA1c, blood pressure, and lipids, demonstrating metabolic benefits beyond weight loss alone.

7 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch